Core Laboratories Inc. CLB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.15% | 0.35% | 1.34% | 0.51% | -1.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.15% | 0.35% | 1.34% | 0.51% | -1.02% |
| Cost of Revenue | 0.91% | 0.41% | 1.15% | -0.70% | -0.38% |
| Gross Profit | -4.40% | 0.12% | 2.10% | 5.43% | -3.50% |
| SG&A Expenses | 8.26% | 12.35% | 11.78% | 14.60% | 12.10% |
| Depreciation & Amortization | 2.29% | 0.84% | -0.88% | -2.03% | -3.42% |
| Other Operating Expenses | 16.13% | 31.34% | 56.66% | 28.30% | 38.21% |
| Total Operating Expenses | 1.68% | 1.60% | 2.37% | 0.65% | 0.74% |
| Operating Income | -18.25% | -11.89% | -8.26% | -0.73% | -15.63% |
| Income Before Tax | -37.12% | -13.68% | 0.52% | -0.63% | -3.04% |
| Income Tax Expenses | 5.91% | -2.58% | -4.35% | 10.48% | -37.86% |
| Earnings from Continuing Operations | -52.23% | -18.25% | 2.91% | -5.48% | 20.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 87.15% | 40.79% | 24.22% | 4.12% | 34.16% |
| Net Income | -51.57% | -17.81% | 3.60% | -5.51% | 22.63% |
| EBIT | -18.25% | -11.89% | -8.26% | -0.73% | -15.63% |
| EBITDA | -13.40% | -8.90% | -6.57% | -1.02% | -13.03% |
| EPS Basic | -50.99% | -16.51% | 5.10% | -4.19% | 23.29% |
| Normalized Basic EPS | -23.06% | -15.42% | -8.49% | 3.87% | -16.26% |
| EPS Diluted | -50.26% | -17.10% | 2.42% | -6.18% | 22.46% |
| Normalized Diluted EPS | -23.06% | -15.42% | -8.39% | 4.42% | -16.03% |
| Average Basic Shares Outstanding | -1.48% | -1.61% | -1.44% | -1.11% | -0.43% |
| Average Diluted Shares Outstanding | -1.39% | -1.58% | -1.52% | -1.64% | -0.96% |
| Dividend Per Share | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Payout Ratio | 1.03% | 0.20% | -0.04% | 0.05% | -0.19% |